Zenocutuzumab

In this edition, robotic-assisted bronchoscopy a ‘game changer’, global mortality related to tobacco drops, particulate matter rises and more.

Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.

The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer.

The FDA announced several regulatory actions the past few weeks.

The FDA granted fast track designation to zenocutuzumab for treatment of patients with metastatic solid tumors that harbor neuregulin 1 fusion cancers that progressed on standard therapy.